You’ve almost certainly heard of these medications by their brand names, usually in the context of weight loss. As an internist, though, the part of the story I find most striking has little to do with the number on the scale. Over the last two years, this class of drugs — the GLP-1 receptor agonists — has been quietly reshaping how we protect the heart and kidneys in some of our highest-risk patients.
What they are. GLP-1 receptor agonists mimic a gut hormone your body already makes after eating. They prompt insulin release, slow stomach emptying, and reduce appetite. That’s why they lower blood sugar and lead to weight loss. The newer surprise is what else they appear to do.
The kidney signal. In 2024, results from the FLOW trial were reported: in people with type 2 diabetes and chronic kidney disease, semaglutide reduced major kidney-disease events by about 24% compared with placebo — the first large trial designed specifically to test a GLP-1 drug’s effect on kidney outcomes. For a complication that quietly pushes people toward dialysis, a result like that is a big deal. It led, in early 2025, to an FDA label expansion recognizing the drug’s role in reducing the risk of worsening kidney disease and cardiovascular death in that population.
The heart signal. Separately, the SELECT trial in people with overweight or obesity and established cardiovascular disease — but without diabetes — supported a 2024 approval for cardiovascular risk reduction. In other words, the benefit wasn’t confined to diabetes. Reviews summarizing the broader body of evidence now describe consistent cardiovascular and kidney benefits across the class, including newer agents like tirzepatide that act on more than one hormone pathway.
Here’s the part that fascinates me. The protective effects appear to be only partly explained by weight loss. Researchers think these drugs also reduce inflammation, improve the lining of blood vessels, and ease the metabolic strain on organs — effects that may operate somewhat independently of how many pounds come off. That reframes them, in my mind, less as “weight-loss drugs” and more as cardiometabolic medications that happen to also reduce weight.
What this does and doesn’t mean for you. These are prescription medications with real side effects — nausea is common, and they aren’t right for everyone. They are not a casual lifestyle purchase, and the online gray market worries me. But for the right patient — particularly someone with diabetes, kidney disease, or established heart disease — the evidence has moved from “promising” to “practice-changing.” If that’s you, it’s a genuine conversation to have with your physician.
This is general information, not medical advice or a recommendation to start or stop any medication.
References
- American Diabetes Association. Semaglutide reduced risk for major kidney disease events by 24% (FLOW trial). diabetes.org
- The Lancet. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. thelancet.com
